Benign Prostate Hyperplasia
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Saku, Magdalene | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Szentmiklósi, József András | |
| dc.contributor.opponentdept | Kenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztály | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2017-07-14T08:23:56Z | |
| dc.date.available | 2017-07-14T08:23:56Z | |
| dc.date.created | 2017-03-28 | |
| dc.description.abstract | Benign prostatic hyperplasia (BPH) also known as benign enlargement of the prostate (BEP or BPE) by definition is the nonmalignant increase in size of the prostate gland. It refers to stromal and glandular epithelial hyperplasia that occurs in the periurethral transition zone of the prostate that surrounds the urethra. Clinically, BPH manifests as lower urinary tract symptoms (LUTS) which consists of irritative (urgency, frequency, nocturia) and obstructive symptoms (hesitancy, weak and interrupted urinary stream, straining to initiate urination, a sensation of incomplete bladder emptying). | hu_HU |
| dc.description.corrector | VÁ | |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 35 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/242581 | |
| dc.language.iso | en | hu_HU |
| dc.subject | Benign Prostate Hyperplasia | hu_HU |
| dc.subject | BPH | |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | Benign Prostate Hyperplasia | hu_HU |